---
document_datetime: 2025-12-02 05:06:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zynteglo.html
document_name: zynteglo.html
version: success
processing_time: 0.1210078
conversion_datetime: 2025-12-28 08:25:59.223194
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zynteglo

[RSS](/en/individual-human-medicine.xml/67204)

##### Withdrawn

This medicine's authorisation has been withdrawn

betibeglogene autotemcel Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zynteglo](#news-on)
- [More information on Zynteglo](#more-information-on-zynteglo-893)
- [More information on Zynteglo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 March 2022, the European Commission withdrew the marketing authorisation for Zynteglo (betibeglogene autotemcel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, bluebird bio (Netherlands) B.V, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Zynteglo was granted conditional marketing authorisation in the EU on 29 May 2019 for treatment of transfusion-dependent β-thalassaemia (TDT). The marketing authorisation was initially valid for a 1 year period. It was subsequently renewed for an additional 1-year period in 2020 and 2021.

The European Public Assessment Report (EPAR) for Zynteglo is updated to indicate that the marketing authorisation is no longer valid.

Zynteglo : EPAR - Medicine overview

Reference Number: EMA/205979/2019

English (EN) (649.46 KB - PDF)

**First published:** 03/06/2019

[View](/en/documents/overview/zynteglo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-631)

български (BG) (730.96 KB - PDF)

**First published:**

03/06/2019

[View](/bg/documents/overview/zynteglo-epar-medicine-overview_bg.pdf)

español (ES) (644.22 KB - PDF)

**First published:**

03/06/2019

[View](/es/documents/overview/zynteglo-epar-medicine-overview_es.pdf)

čeština (CS) (712.13 KB - PDF)

**First published:**

03/06/2019

[View](/cs/documents/overview/zynteglo-epar-medicine-overview_cs.pdf)

dansk (DA) (646.26 KB - PDF)

**First published:**

03/06/2019

[View](/da/documents/overview/zynteglo-epar-medicine-overview_da.pdf)

Deutsch (DE) (648.14 KB - PDF)

**First published:**

03/06/2019

[View](/de/documents/overview/zynteglo-epar-medicine-overview_de.pdf)

eesti keel (ET) (639.16 KB - PDF)

**First published:**

03/06/2019

[View](/et/documents/overview/zynteglo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (732.57 KB - PDF)

**First published:**

03/06/2019

[View](/el/documents/overview/zynteglo-epar-medicine-overview_el.pdf)

français (FR) (645.79 KB - PDF)

**First published:**

03/06/2019

[View](/fr/documents/overview/zynteglo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (657.94 KB - PDF)

**First published:**

03/06/2019

[View](/hr/documents/overview/zynteglo-epar-medicine-overview_hr.pdf)

italiano (IT) (645.32 KB - PDF)

**First published:**

03/06/2019

[View](/it/documents/overview/zynteglo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (714.35 KB - PDF)

**First published:**

03/06/2019

[View](/lv/documents/overview/zynteglo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (665.21 KB - PDF)

**First published:**

03/06/2019

[View](/lt/documents/overview/zynteglo-epar-medicine-overview_lt.pdf)

magyar (HU) (697.91 KB - PDF)

**First published:**

03/06/2019

[View](/hu/documents/overview/zynteglo-epar-medicine-overview_hu.pdf)

Malti (MT) (715.86 KB - PDF)

**First published:**

03/06/2019

[View](/mt/documents/overview/zynteglo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (643.21 KB - PDF)

**First published:**

03/06/2019

[View](/nl/documents/overview/zynteglo-epar-medicine-overview_nl.pdf)

polski (PL) (711.85 KB - PDF)

**First published:**

03/06/2019

[View](/pl/documents/overview/zynteglo-epar-medicine-overview_pl.pdf)

português (PT) (644.8 KB - PDF)

**First published:**

03/06/2019

[View](/pt/documents/overview/zynteglo-epar-medicine-overview_pt.pdf)

română (RO) (663.82 KB - PDF)

**First published:**

03/06/2019

[View](/ro/documents/overview/zynteglo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (714.2 KB - PDF)

**First published:**

03/06/2019

[View](/sk/documents/overview/zynteglo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (707.57 KB - PDF)

**First published:**

03/06/2019

[View](/sl/documents/overview/zynteglo-epar-medicine-overview_sl.pdf)

Suomi (FI) (646.13 KB - PDF)

**First published:**

03/06/2019

[View](/fi/documents/overview/zynteglo-epar-medicine-overview_fi.pdf)

svenska (SV) (647.56 KB - PDF)

**First published:**

03/06/2019

[View](/sv/documents/overview/zynteglo-epar-medicine-overview_sv.pdf)

Zynteglo : EPAR - Risk-management-plan summary

English (EN) (220.91 KB - PDF)

**First published:** 03/06/2019

**Last updated:** 04/10/2021

[View](/en/documents/rmp-summary/zynteglo-epar-risk-management-plan-summary_en.pdf)

## Product information

Zynteglo : EPAR - Product information

English (EN) (5.36 MB - PDF)

**First published:** 03/06/2019

**Last updated:** 20/01/2022

[View](/en/documents/product-information/zynteglo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-866)

български (BG) (5.88 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/bg/documents/product-information/zynteglo-epar-product-information_bg.pdf)

español (ES) (4.71 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/es/documents/product-information/zynteglo-epar-product-information_es.pdf)

čeština (CS) (5.61 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/cs/documents/product-information/zynteglo-epar-product-information_cs.pdf)

dansk (DA) (5.33 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/da/documents/product-information/zynteglo-epar-product-information_da.pdf)

Deutsch (DE) (4.83 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/de/documents/product-information/zynteglo-epar-product-information_de.pdf)

eesti keel (ET) (5.29 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/et/documents/product-information/zynteglo-epar-product-information_et.pdf)

ελληνικά (EL) (6.6 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/el/documents/product-information/zynteglo-epar-product-information_el.pdf)

français (FR) (4.16 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/fr/documents/product-information/zynteglo-epar-product-information_fr.pdf)

hrvatski (HR) (10.58 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/hr/documents/product-information/zynteglo-epar-product-information_hr.pdf)

íslenska (IS) (4.83 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/is/documents/product-information/zynteglo-epar-product-information_is.pdf)

italiano (IT) (4.71 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/it/documents/product-information/zynteglo-epar-product-information_it.pdf)

latviešu valoda (LV) (5.45 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/lv/documents/product-information/zynteglo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.71 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/lt/documents/product-information/zynteglo-epar-product-information_lt.pdf)

magyar (HU) (5.03 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/hu/documents/product-information/zynteglo-epar-product-information_hu.pdf)

Malti (MT) (5.6 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/mt/documents/product-information/zynteglo-epar-product-information_mt.pdf)

Nederlands (NL) (4.87 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/nl/documents/product-information/zynteglo-epar-product-information_nl.pdf)

norsk (NO) (14.2 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/no/documents/product-information/zynteglo-epar-product-information_no.pdf)

polski (PL) (4.09 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/pl/documents/product-information/zynteglo-epar-product-information_pl.pdf)

português (PT) (5.11 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/pt/documents/product-information/zynteglo-epar-product-information_pt.pdf)

română (RO) (4.98 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/ro/documents/product-information/zynteglo-epar-product-information_ro.pdf)

slovenčina (SK) (4.98 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/sk/documents/product-information/zynteglo-epar-product-information_sk.pdf)

slovenščina (SL) (5.55 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/sl/documents/product-information/zynteglo-epar-product-information_sl.pdf)

Suomi (FI) (5.23 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/fi/documents/product-information/zynteglo-epar-product-information_fi.pdf)

svenska (SV) (4.81 MB - PDF)

**First published:**

03/06/2019

**Last updated:**

20/01/2022

[View](/sv/documents/product-information/zynteglo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0030 09/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zynteglo : EPAR - All authorised presentations

English (EN) (598.58 KB - PDF)

**First published:** 03/06/2019

[View](/en/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-322)

български (BG) (635.96 KB - PDF)

**First published:**

03/06/2019

[View](/bg/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_bg.pdf)

español (ES) (598.82 KB - PDF)

**First published:**

03/06/2019

[View](/es/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (630.41 KB - PDF)

**First published:**

03/06/2019

[View](/cs/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (599.94 KB - PDF)

**First published:**

03/06/2019

[View](/da/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (599.81 KB - PDF)

**First published:**

03/06/2019

[View](/de/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (598.19 KB - PDF)

**First published:**

03/06/2019

[View](/et/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (635.62 KB - PDF)

**First published:**

03/06/2019

[View](/el/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_el.pdf)

français (FR) (598.07 KB - PDF)

**First published:**

03/06/2019

[View](/fr/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (669.61 KB - PDF)

**First published:**

03/06/2019

[View](/hr/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (599.58 KB - PDF)

**First published:**

03/06/2019

[View](/is/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (597.66 KB - PDF)

**First published:**

03/06/2019

[View](/it/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (630.98 KB - PDF)

**First published:**

03/06/2019

[View](/lv/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (616.84 KB - PDF)

**First published:**

03/06/2019

[View](/lt/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (622.28 KB - PDF)

**First published:**

03/06/2019

[View](/hu/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (633.26 KB - PDF)

**First published:**

03/06/2019

[View](/mt/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (598.51 KB - PDF)

**First published:**

03/06/2019

[View](/nl/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (599.93 KB - PDF)

**First published:**

03/06/2019

[View](/no/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_no.pdf)

polski (PL) (56.52 KB - PDF)

**First published:**

03/06/2019

[View](/pl/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_pl.pdf)

português (PT) (599.03 KB - PDF)

**First published:**

03/06/2019

[View](/pt/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_pt.pdf)

română (RO) (615.57 KB - PDF)

**First published:**

03/06/2019

[View](/ro/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (630.04 KB - PDF)

**First published:**

03/06/2019

[View](/sk/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (630.26 KB - PDF)

**First published:**

03/06/2019

[View](/sl/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (597.5 KB - PDF)

**First published:**

03/06/2019

[View](/fi/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (598.3 KB - PDF)

**First published:**

03/06/2019

[View](/sv/documents/all-authorised-presentations/zynteglo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zynteglo Active substance autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene International non-proprietary name (INN) or common name betibeglogene autotemcel Therapeutic area (MeSH) beta-Thalassemia Anatomical therapeutic chemical (ATC) code B06A

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Zynteglo is indicated for the treatment of patients 12 years and older with transfusion-dependent β thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

## Authorisation details

EMA product number EMEA/H/C/003691

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

bluebird bio (Netherlands) B.V.

Stadsplateau 7

Opinion adopted 28/03/2019 Marketing authorisation issued 29/05/2019 Withdrawal of marketing authorisation 24/03/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zynteglo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (778.09 KB - PDF)

**First published:** 14/11/2019

**Last updated:** 10/12/2021

[View](/en/documents/procedural-steps-after/zynteglo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Zynteglo : EPAR - Scientific conclusions

English (EN) (658.3 KB - PDF)

**First published:** 04/10/2021

[View](/en/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-353)

български (BG) (806.82 KB - PDF)

**First published:**

04/10/2021

[View](/bg/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_bg.pdf)

español (ES) (672.9 KB - PDF)

**First published:**

04/10/2021

[View](/es/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_es.pdf)

čeština (CS) (749.31 KB - PDF)

**First published:**

04/10/2021

[View](/cs/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_cs.pdf)

dansk (DA) (669.68 KB - PDF)

**First published:**

04/10/2021

[View](/da/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (676.05 KB - PDF)

**First published:**

04/10/2021

[View](/de/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (664.18 KB - PDF)

**First published:**

04/10/2021

[View](/et/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (811.21 KB - PDF)

**First published:**

04/10/2021

[View](/el/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_el.pdf)

français (FR) (669.11 KB - PDF)

**First published:**

04/10/2021

[View](/fr/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (677.26 KB - PDF)

**First published:**

04/10/2021

[View](/hr/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_hr.pdf)

italiano (IT) (685.19 KB - PDF)

**First published:**

04/10/2021

[View](/it/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (777 KB - PDF)

**First published:**

04/10/2021

[View](/lv/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (716.37 KB - PDF)

**First published:**

04/10/2021

[View](/lt/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_lt.pdf)

magyar (HU) (754.71 KB - PDF)

**First published:**

04/10/2021

[View](/hu/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_hu.pdf)

Malti (MT) (777.14 KB - PDF)

**First published:**

04/10/2021

[View](/mt/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (691.24 KB - PDF)

**First published:**

04/10/2021

[View](/nl/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_nl.pdf)

polski (PL) (761.76 KB - PDF)

**First published:**

04/10/2021

[View](/pl/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_pl.pdf)

português (PT) (696.53 KB - PDF)

**First published:**

04/10/2021

[View](/pt/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_pt.pdf)

română (RO) (705.72 KB - PDF)

**First published:**

04/10/2021

[View](/ro/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (754.7 KB - PDF)

**First published:**

04/10/2021

[View](/sk/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (758.31 KB - PDF)

**First published:**

04/10/2021

[View](/sl/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (687.9 KB - PDF)

**First published:**

04/10/2021

[View](/fi/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_fi.pdf)

svenska (SV) (668.07 KB - PDF)

**First published:**

04/10/2021

[View](/sv/documents/scientific-conclusion/zynteglo-epar-scientific-conclusions_sv.pdf)

Zynteglo-H-20-1504-C-003691-0023 : EPAR - PRAC assessment report

Adopted

Reference Number: EMA/418200/2021

English (EN) (489.78 KB - PDF)

**First published:** 04/10/2021

[View](/en/documents/variation-report/zynteglo-h-20-1504-c-003691-0023-epar-prac-assessment-report_en.pdf)

## Initial marketing authorisation documents

Zynteglo : EPAR - Public assessment report

Adopted

Reference Number: EMA/56140/2020

English (EN) (5.58 MB - PDF)

**First published:** 03/06/2019

**Last updated:** 14/02/2020

[View](/en/documents/assessment-report/zynteglo-epar-public-assessment-report_en.pdf)

Zynteglo : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/263767/2019

English (EN) (608.8 KB - PDF)

**First published:** 03/06/2019

**Last updated:** 30/11/2022

[View](/en/documents/orphan-maintenance-report/zynteglo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Zynteglo

Adopted

Reference Number: EMA/CHMP/166977/2019

English (EN) (633.8 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zynteglo_en.pdf)

#### News on Zynteglo

[CHMP endorses review finding no link between viral vector in Zynteglo and blood cancer](/en/news/chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-blood-cancer) 23/07/2021

[EMA finds no evidence linking viral vector in Zynteglo to blood cancer](/en/news/ema-finds-no-evidence-linking-viral-vector-zynteglo-blood-cancer) 09/07/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021) 09/07/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-march-2021) 12/03/2021

[Precautionary marketing suspension of thalassaemia medicine Zynteglo](/en/news/precautionary-marketing-suspension-thalassaemia-medicine-zynteglo) 17/02/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019) 29/03/2019

[New gene therapy to treat rare inherited blood condition](/en/news/new-gene-therapy-treat-rare-inherited-blood-condition) 29/03/2019

#### More information on Zynteglo

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-12-1091) on 24 January 2013. Zynteglo was withdrawn from the Community register of orphan medicinal products by the European Commission in March 2022 at the time of the withdrawal of the marketing authorisation.

#### More information on Zynteglo

- [EMEA-001665-PIP01-14-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001665-pip01-14-m06)
- [Zynteglo - referral](/en/medicines/human/referrals/zynteglo)
- [REG-501: A Registry of Patients with β-Thalassemia Treated with Betibeglogene Autotemcel - post-authorisation study](https://catalogues.ema.europa.eu/study/42440)
- [A Non-Interventional Registry Study of Patients with β-thalassemia to Characterise and Contextualise the Safety and Effectiveness of Betibeglogene Autotemcel - post-authorisation study](https://catalogues.ema.europa.eu/study/46901)

**This page was last updated on** 30/11/2022

## Share this page

[Back to top](#main-content)